Global life sciences company Astellas Pharma has secured $26.0M in a Series B funding round, bolstering its mission to deliver transformative therapies. The capital infusion will support its research and development programs, which are focused on pioneering new healthcare solutions for diseases with high unmet medical need, including oncology, ophthalmology, urology, immunology, and women's health.
The round saw participation from a group of investors including AVP, Yaday Health, Blast Club, Omnes Capital, and Debiopharm Innovation Fund, signaling continued confidence in Astellas's approach to turning innovative science into value for patients.


















